A Step Closer to Vision Restoration: Nanoscope Therapeutics Fortifies Partnership with Catalent for MCO-010
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in therapeutic development offers a beacon of hope. A significant update comes from Nanoscope Therapeutics, which has expanded its partnership with Catalent to support the late-phase development and commercial supply of its lead optogenetic gene therapy, MCO-010. This collaboration signals a crucial step forward in making a potential new treatment accessible to the IRD community.
MCO-010 is an investigational optogenetic gene therapy designed to restore vision in patients with advanced retinal degenerative diseases, including retinitis pigmentosa (RP) and Stargardt disease. This innovative approach works by reprogramming retinal cells to become light-sensitive, offering a potential solution for those with late-stage disease where therapeutic options are currently limited.
The expanded partnership, announced on July 7, 2026, focuses on Catalent providing commercial-compliant packaging and distribution for MCO-010. This includes securing the commercial packaging validation program to support Nanoscope's Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), a rolling submission for which is currently underway. Catalent's role is critical in ensuring that MCO-010 can be scaled to meet global commercialization needs, as highlighted by Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics.
This collaboration underscores the commitment of both companies to bring MCO-010 to market. Ricky Hopson, Group President, Clinical & Specialty Services and Chief of Staff at Catalent, expressed the company's dedication to supporting Nanoscope at every stage to make vision restoration a reality for patients worldwide. Nanoscope has previously reported positive results from its RESTORE Phase 2b/3 clinical trial for retinitis pigmentosa, with visual acuity gains observed through three years in ongoing long-term follow-up, and no serious adverse events reported in treated eyes.
For patients and their families, this expanded partnership means that the infrastructure for potential broad availability of MCO-010 is being actively developed. The focus on commercial supply and distribution indicates that Nanoscope and Catalent are preparing for the possibility of regulatory approval, which could significantly impact the lives of those affected by RP and Stargardt disease. MCO-010 is designed to be a one-time, in-office intravitreal injection that does not require genetic testing or surgical intervention, making it potentially applicable to a broad population of RP patients.
As the rolling BLA submission continues, the IRD community will be closely watching for further updates on MCO-010's journey toward potential approval and commercialization.